signific
interplay
innat
adapt
immun
control
respons
respiratori
viral
influenza
upon
infect
human
cell
recogn
pattern
recognit
receptor
lead
mobil
innat
immun
system
secret
chemokin
sequenc
event
neighbor
innat
immun
cell
activ
transform
growth
latent
form
result
secret
chemokin
interleukin
parenchym
inflammatori
initi
phase
immun
respons
crucial
role
contribut
proinflammatori
cytokin
member
interleukin
superfamili
like
cytokin
infect
macrophag
dendrit
cell
dc
activ
pyrin
protein
inflammasom
trigger
cytokin
product
addit
type
type
iii
interferon
secret
block
viru
replic
infect
well
plasmatocytoid
dc
time
b
cell
secret
antibodi
mediat
adapt
immun
end
result
either
host
resist
toler
promot
tissu
cascad
cytokin
secret
respons
sever
clinic
symptom
sign
associ
influenza
syndrom
besid
clinic
syndrom
durat
extent
inflammatori
respons
may
lead
patholog
local
tissu
level
although
clearli
associ
viral
infect
cell
may
play
import
role
maintain
mucos
barrier
contribut
pathogen
clearanc
mucos
surfac
limit
avail
knowledg
role
pathway
respons
human
host
respiratori
viru
infect
experiment
model
cytokin
propos
associ
modul
inflamm
may
benefici
clearanc
influenza
howev
other
suggest
potenti
role
increas
diseas
relat
sever
anim
limit
data
suggest
associ
exagger
system
respons
sever
diseas
respiratori
involv
patient
suffer
pandem
influenza
caus
current
studi
evalu
cytokin
profil
pilot
studi
respiratori
viru
infect
molecular
test
use
viru
identif
consecut
patient
symptom
respiratori
tract
infect
visit
emerg
depart
er
tertiari
care
hospit
evalu
winter
season
pharyng
swab
specimen
taken
consecut
patient
outpati
present
er
symptom
respiratori
tract
infect
headach
malais
accompani
either
cough
sore
throat
nasal
congest
without
fever
sampl
collect
everi
call
day
hospit
everi
day
period
octob
april
basic
clinic
epidemiolog
characterist
collect
structur
case
report
form
nasopharyng
swab
store
thin
prep
cytol
solut
cytyc
corpor
malborough
immedi
sent
laboratori
analysi
clart
pneumovir
kit
genomica
spain
use
viral
detect
known
respiratori
virus
accord
manufactur
protocol
briefli
viral
rna
extract
thin
prep
cytolyt
cytyc
corpor
boxborough
solut
use
magmax
viral
rna
isol
kit
thermo
fisher
foster
citi
ca
elut
elut
buffer
thin
prep
cytol
solut
clinic
sampl
centrifug
minut
pellet
place
thin
prep
preservcyt
vial
molecular
test
respiratori
virus
clart
pneumovir
kit
use
genomica
capabl
detect
character
presenc
frequent
type
human
virus
caus
respiratori
infect
common
clinic
sampl
virus
analyz
includ
influenza
viru
b
c
piv
subtyp
b
respiratori
syncyti
viru
type
rhinoviru
human
metapneumoviru
hmpv
subtyp
b
enteroviru
echoviru
adenoviru
coronaviru
bocaviru
molecular
procedur
follow
accord
manufactur
instruct
briefli
thin
prep
preservcyt
solut
use
viral
dnarna
extract
viru
amplif
perform
via
two
revers
transcriptas
multiplex
polymeras
chain
reaction
detectionvisu
perform
base
microarray
neg
control
includ
experi
point
care
test
maripoc
arcdia
intern
oy
ltd
turku
finland
autom
multianalyt
antigen
test
use
conjunct
clinic
array
system
second
test
use
provid
result
within
hour
test
thu
assist
manag
decis
regard
discharg
patient
emerg
depart
addit
examin
presenc
streptococcu
pneumonia
antigen
conjunct
posit
result
two
method
use
consid
analysi
five
case
three
influenza
one
hmpv
one
bocaviru
infect
poc
test
neg
array
test
cytokin
profil
evalu
milliplex
map
human
magnet
bead
panel
kit
use
simultan
quantif
follow
cytokin
known
involv
cytokin
chosen
involv
cascad
correl
profil
viral
detect
clinic
characterist
eg
age
sex
presenc
comorbid
like
chronic
obstruct
pulmonari
diseas
cardiovascular
diseas
diabet
malign
histori
vaccin
sever
diseas
requir
hospit
well
laboratori
paramet
eg
protein
level
white
blood
cell
count
wbc
particip
subject
perform
univari
multivari
analysi
cytokin
level
examin
six
healthi
volunt
evid
respiratori
infect
comorbid
viru
posit
correl
use
fisher
exact
test
cytokin
level
correl
detect
viru
posit
well
detect
specif
virus
eg
influenza
influenza
b
nonparametr
test
independ
sampl
test
also
perform
analysi
varianc
anova
compar
cytokin
level
group
viru
identif
influenza
posit
influenza
posit
rsv
posit
piv
posit
viru
posit
least
signific
iffer
ie
lsd
post
hoc
test
report
appropri
accord
leven
homogen
varianc
test
welch
test
equal
mean
mix
infect
analyz
separ
ad
individu
viru
contribut
mix
infect
number
look
cytokin
interrel
use
spearman
correl
coeffici
correl
symptom
viru
detect
perform
univari
analysi
separ
examin
influenza
influenza
b
rsv
piv
infect
compar
viru
detect
multivari
analysi
examin
factor
associ
sever
diseas
need
hospit
use
logist
regress
specif
factor
statist
signific
p
includ
multivari
analys
final
model
effect
potenti
confound
variabl
associ
level
eg
wbc
presenc
comorbid
fever
fever
height
clinic
laboratori
paramet
well
interact
term
includ
statist
model
statist
test
data
analysi
perform
use
spss
program
version
spss
chicago
il
written
inform
consent
obtain
particip
patient
studi
approv
institut
review
board
hospit
patient
evalu
median
age
year
interquartil
rang
iqr
year
femal
respiratori
viru
identifi
patient
tabl
patient
confirm
influenza
infect
seven
mix
anoth
viru
specif
three
rsv
two
adenoviru
one
piv
one
rhinoviru
piv
infect
one
mix
infect
influenza
nine
rsv
infect
three
mix
influenza
b
overal
eight
patient
mix
viral
infect
regard
virus
four
patient
hmpv
detect
four
patient
rhinoviru
two
patient
adenoviru
one
patient
bocaviru
infect
patient
diagnos
rsv
infect
averag
older
patient
diagnos
influenza
viru
infect
p
anova
tabl
influenza
patient
type
b
fever
compar
patient
viru
detect
patient
rsv
piv
infect
p
anova
patient
admit
stay
longer
hospit
compar
type
virus
p
comparison
anova
laboratori
cytokin
data
per
specif
viru
infect
patient
studi
depict
tabl
data
addit
shown
six
healthi
volunt
significantli
lower
cytokin
valu
rest
group
p
comparison
tabl
elev
protein
level
valu
note
patient
seen
tabl
normal
valu
less
mgl
highest
protein
level
valu
seen
piv
detect
reach
statist
signific
compar
level
seen
virus
includ
type
influenza
rsv
viru
detect
p
comparison
anova
piv
addit
associ
higher
wbc
polymorphonuclear
cell
count
pmn
compar
viru
detect
influenza
influenza
b
p
anova
tabl
figur
influenza
b
lowest
wbc
overal
lower
wbc
pmn
compar
rsv
viru
detect
p
anova
tabl
figur
viru
detect
n
patient
influenza
detect
overal
group
n
associ
cytokin
examin
specif
virus
influenza
associ
higher
level
compar
peopl
present
uri
symptom
respiratori
viru
detect
p
anova
post
hoc
test
p
level
approach
statist
signific
furthermor
influenza
infect
associ
higher
level
compar
rsv
infect
viru
infect
p
anova
post
hoc
test
tabl
figur
addit
influenza
higher
level
sever
cytokin
like
compar
b
influenza
p
anova
post
hoc
test
figur
piv
similarli
higher
level
compar
detect
rsv
influenza
b
viru
infect
p
anova
post
hoc
test
tabl
figur
increas
age
correl
posit
hematolog
paramet
includ
wbc
pmn
spearman
rho
respect
p
lengthier
hospit
spearman
rho
p
neg
fever
level
spearman
rho
respect
p
highli
correl
cytokin
spearman
rho
p
identifi
signific
associ
cascad
specif
clinic
paramet
like
presenc
fever
height
fever
eg
wheez
myalgia
presenc
dri
product
cough
presenc
nasal
symptom
show
statist
signific
neg
correl
studi
cytokin
except
p
sampl
test
logist
regress
model
adjust
age
presenc
comorbid
interact
term
wbc
crp
level
level
found
age
ci
p
well
level
ci
p
predict
sever
diseas
hospit
admiss
correctli
case
increas
level
main
cell
effector
cytokin
identifi
influenza
compar
type
influenza
rsv
respiratori
virus
pilot
studi
excess
amount
cytokin
may
implic
pathogenesi
immun
control
acut
influenza
infect
similar
observ
piv
infect
may
indic
role
pathway
parainfluenza
infect
unclear
involv
immun
respons
influenza
piv
infect
crucial
role
inflamm
found
microbi
hand
uncontrol
signal
associ
autoimmun
diseas
even
cancer
specif
famili
member
discret
role
human
immun
eg
mainli
involv
mucos
host
defens
mechan
wherea
amplifi
immun
last
year
studi
examin
role
pathway
human
influenza
none
knowledg
human
respiratori
infect
comparison
virus
affect
respiratori
tract
recent
literatur
suggest
adapt
immun
may
involv
clearanc
influenza
virus
respiratori
tract
immun
system
patient
suffer
influenza
respond
releas
sever
proinflammatori
among
cascad
appear
central
role
symptom
gener
local
inflammatori
clinic
relev
cytokin
storm
recruit
neutrophil
monocyt
macrophag
site
may
associ
sever
diseas
outcom
appear
depend
pathogen
viru
host
respons
role
process
clearli
delin
yet
although
import
increasingli
studi
shown
posit
associ
mild
increas
two
studi
patient
sever
affect
pandem
viru
higher
level
note
milder
case
find
consist
one
studi
mark
suppress
adapt
immun
influenza
compar
season
type
type
b
anoth
studi
pediatr
infect
novel
pandem
viru
higher
level
seen
patient
pandem
infect
compar
control
pneumonia
attribut
caus
moreov
higher
correl
diseas
nevertheless
studi
differ
mildli
sever
affect
increas
patient
suffer
diffus
alveolar
damag
seen
one
experiment
lung
immunopatholog
autopsi
studi
patient
affect
pandem
patient
pandem
influenza
beij
elev
level
mediat
respons
cytokin
detect
author
perform
influenza
experi
mice
show
milder
diseas
defici
anim
anim
treat
hand
downregul
respons
sever
influenza
may
lead
function
impair
delay
viral
clearanc
sustain
proinflammatori
respons
dysregul
adapt
immun
variou
factor
affect
interplay
viru
pathogen
host
regard
rsv
observ
limit
literatur
suggest
role
cytokin
rsv
one
infant
studi
level
associ
reduct
clinic
symptom
respiratori
lower
level
cytokin
patient
rsv
studi
might
contribut
inabl
properli
control
host
inflammatori
respons
lead
seriou
diseas
pattern
sicker
patient
rsv
hospit
longer
regard
associ
clinic
symptom
cytokin
profil
observ
signific
associ
except
neg
correl
presenc
nasal
symptom
probabl
indic
presenc
influenza
virus
nevertheless
piv
posit
subject
nasal
symptom
differ
far
cytokin
profil
without
symptom
suggest
observ
effect
cytokin
independ
local
symptomatolog
possibl
low
sampl
size
permit
us
find
signific
cytokin
effect
relat
clinic
paramet
strength
studi
includ
first
literatur
test
sever
famili
cytokin
across
spectrum
viral
infect
show
clear
increas
level
sever
cytokin
belong
famili
associ
influenza
piv
infect
find
studi
assist
develop
test
hypothes
regard
use
famili
cytokin
therapeut
target
influenza
piv
respiratori
infect
specif
cytokin
use
biomark
regard
sever
diseas
certain
viral
infect
limit
studi
includ
pilot
natur
small
amount
observ
exampl
fact
could
verifi
seen
respons
influenza
viru
infect
may
due
limit
number
observ
patient
affect
pandem
viru
furthermor
studi
dynam
evolut
marker
cours
viral
infect
thu
studi
snapshot
mild
moder
ill
patient
show
emerg
depart
tertiari
care
center
possibl
miss
patient
milder
pictur
quickli
clear
viru
system
like
patient
viru
detect
studi
thu
miss
full
spectrum
respons
respiratori
viral
infect
sampl
site
exampl
nasal
sampl
bal
sever
case
would
assist
better
understand
differencesynergi
local
compar
system
cytokin
effect
addit
although
care
record
analyz
data
variabl
potenti
advers
affect
effect
immun
respons
could
account
residu
confound
studi
hypothes
mechan
behind
differ
cytokin
profil
observ
influenza
b
effort
influenza
b
infect
remain
less
studi
influenza
human
anim
despit
fact
associ
signific
number
respiratori
infect
case
contrari
find
studi
patient
compar
cytokin
level
type
vs
type
b
influenza
hallmark
cytokin
cell
subset
along
level
significantli
higher
type
b
less
virul
circul
b
strain
could
explain
find
anim
studi
use
model
influenza
b
infect
cytokin
panel
includ
evid
import
contribut
moreov
differ
degre
immunopatholog
caus
two
differ
influenza
b
virus
victoria
lineag
viru
virul
associ
greater
morbid
lethal
interestingli
period
studi
main
influenza
b
strain
across
europ
greec
belong
yamagata
due
small
sampl
studi
differ
verifi
studi
would
specif
examin
differ
lineag
viru
final
role
effect
influenza
system
assess
effort
exampl
mous
model
respiratori
influenza
signific
respons
intestin
associ
immun
intestin
injuri
develop
diarrhea
note
furthermor
neutral
reduc
intestin
intestin
microbiota
chang
relat
influenza
cytokin
chang
interest
field
human
research
could
assess
current
conclus
describ
famili
cytokin
level
associ
respiratori
viral
infect
confirm
molecular
method
pilot
studi
studi
patient
respiratori
viral
infect
would
assist
concur
understand
observ
upregul
main
cell
effector
cytokin
relat
specif
type
respiratori
virus
associ
especi
one
observ
influenza
piv
novel
merit
consider
even
find
come
small
pilot
futur
verif
studi
result
well
exploit
cytokin
pathway
diagnost
therapeut
prognost
purpos
may
greatli
assist
manag
common
potenti
seriou
viral
respiratori
infect
necessari
